Peter A. Altman

Comments on 'The mechanical properties of the rabbit and human cornea'.

David A. Hoeltzel, Peter A. Altman, 1991, Journal of biomechanics.

Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study).

Peter A. Altman, D. Rouy, S. Stertzer, 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study).

Peter A. Altman, S. Stertzer, L. M. de la Fuente, 2007, American heart journal.

Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Darcy L. DiFede, Peter A. Altman, R. Hendel, 2014, JAMA.

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.

Joshua M Hare, Phillip Ruiz, Peter A. Altman, 2012, JAMA.

Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart.

Peter A. Altman, D. Rouy, W. Pyun, 2017, International heart journal.

Evaluation of the percutaneous intramyocardial injection for local myocardial treatment

Peter A. Altman, A. Yeung, R. Schwartz, 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy: Functional Recovery and Reverse Remodeling

Peter A. Altman, P. Pattany, A. Heldman, 2011, Circulation research.

Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally?: An Analysis From the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) Randomized Trial

Peter A. Altman, Katarina H. Nelson, A. Lardo, 2014, Circulation research.

Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally?Novelty and Significance

Peter A. Altman, Katarina H. Nelson, A. Lardo, 2014 .

Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi

Peter A. Altman, A. Heldman, D. Rouy, 2011, American heart journal.

The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high‐dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design

Peter A. Altman, A. Raval, C. Pepine, 2018, American heart journal.

Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort.

Peter A. Altman, A. Raval, C. Pepine, 2020, International journal of cardiology.

Exploring heart lymphatics in local drug delivery.

Peter A. Altman, R. Sievers, Randall G. Lee, 2003, Lymphatic research and biology.